Summary
Zoetis Inc. reported robust performance for the fiscal year ended December 31, 2020, with total revenue reaching $6.68 billion, a 7% increase year-over-year. This growth was primarily driven by strong performance in companion animal products, which saw a 16% increase in revenue, and a 3% operational revenue growth in international markets. The company's financial health remained solid, supported by healthy operating cash flows. Zoetis continues to invest significantly in research and development, allocating $463 million in 2020 to drive innovation and expand its product lifecycle. Key product lines like Apoquel and the Simparica franchise demonstrated strong revenue contribution, underscoring the company's focus on high-demand therapeutic areas. Despite facing economic uncertainties and the ongoing impact of COVID-19, Zoetis maintained its market leadership position in the animal health industry.
Financial Highlights
55 data points| Revenue | $6.67B |
| Cost of Revenue | $2.06B |
| Gross Profit | $4.62B |
| SG&A Expenses | $1.73B |
| Interest Expense | $231.00M |
| Net Income | $1.64B |
| EPS (Basic) | $3.44 |
| EPS (Diluted) | $3.42 |
| Shares Outstanding (Basic) | 475.50M |
| Shares Outstanding (Diluted) | 478.57M |
Key Highlights
- 1Total revenue increased by 7% to $6.68 billion in 2020, driven by strong companion animal product sales (+16%) and international operational growth (+7%).
- 2The company invested $463 million in Research and Development (R&D) to fuel innovation and product lifecycle expansion.
- 3Top products like Apoquel and the Simparica franchise, along with other key products (Revolution, Draxxin, ceftiofur line), collectively contributed 31% of total revenue, demonstrating product concentration.
- 4Zoetis reported solid net income of $1.64 billion, a 9% increase year-over-year, and maintained effective cost management with cost of sales as a percentage of revenue decreasing to 31%.
- 5The U.S. segment revenue grew by 11% to $3.56 billion, with companion animal products being the primary driver, while the international segment saw a 2% revenue increase, despite a 5% negative impact from foreign exchange.
- 6The company maintained a strong liquidity position with $3.60 billion in cash and cash equivalents as of December 31, 2020.
- 7Zoetis continued its strategic acquisitions, including Fish Vet Group, Virtual Recall, Performance Livestock Analytics, and Ethos Diagnostic Science, to expand its offerings in diagnostics, data analytics, and precision livestock farming.